Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes

Current Diabetes Reports
Anastasia-Stefania AlexopoulosJohn R Guyton

Abstract

Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)-the "diabetic dyslipidemia" phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients. In the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population. Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.

References

Jul 1, 1984·The Journal of Clinical Investigation·P J NestelR Boston
Aug 15, 1994·Annals of Internal Medicine·D R GrayM L Kashyap
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Aug 23, 2000·The Journal of Clinical Investigation·H N Ginsberg
Mar 10, 2004·The American Journal of Medicine·Robert S Rosenson
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Apr 11, 2008·Clinical Science·Esther M M OoiGerald F Watts
Jul 19, 2008·The New England Journal of Medicine·Iris ShaiUNKNOWN Dietary Intervention Randomized Controlled Trial (DIRECT) Group
Mar 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ann AlbrightDesmond E Williams
Aug 8, 2009·Journal of the American College of Cardiology·Carl J LavieHector O Ventura
Sep 18, 2009·Expert Opinion on Investigational Drugs·Manfredi RizzoKaspar Berneis
Feb 16, 2010·Pharmacology & Therapeutics·M John ChapmanPhilippe Giral
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Jan 19, 2011·Gene·Antonis D LampidonisDimitrios J Stravopodis
Mar 12, 2011·Journal of Clinical Lipidology·James D OtvosDavid C Goff
May 17, 2011·Diabetes, Obesity & Metabolism·A Chaudhuri, P Dandona
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 30, 2011·Current Opinion in Lipidology·Sarah Farr, Khosrow Adeli
Jun 13, 2012·The New England Journal of Medicine·Jackie BoschSalim Yusuf
Sep 11, 2012·The Journal of Clinical Endocrinology and Metabolism·Lars BerglundUNKNOWN Endocrine society
May 10, 2013·The New England Journal of Medicine·UNKNOWN Risk and Prevention Study Collaborative GroupRoberto Marchioli
Sep 26, 2013·Nature Reviews. Cardiology·Gerald F WattsDick C Chan
Jan 18, 2014·Clinical Chemistry·Mette ThomsenBørge G Nordestgaard
Jan 30, 2014·European Heart Journal·Michael V HolmesJuan P Casas
Apr 1, 2014·JAMA : the Journal of the American Medical Association·A Michael LincoffUNKNOWN AleCardio Investigators
Jun 19, 2014·The New England Journal of Medicine·Jacy CrosbySekar Kathiresan

❮ Previous
Next ❯

Citations

Mar 4, 2021·Current Cardiology Reports·Ehete BahiruKarol E Watson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Related Papers

European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
Stephen J NichollsJean-Claude Tardif
Vascular Health and Risk Management
Daniel J Scherer, Stephen J Nicholls
Current Treatment Options in Cardiovascular Medicine
Nadia Khoury, Anne Carol Goldberg
© 2022 Meta ULC. All rights reserved